Demographic and clinical characteristics of ITP cases in CAMMS223
| Subject ID . | Age at ITP onset, y (sex) . | No. of alemtuzumab cycles (cumulative dose, mg) . | Months from first dose (last dose) to ITP onset . | Platelet count nadir, 109/L . | Presenting signs or symptoms . | ITP therapy . | Months from ITP onset to CR . | Duration of CR at last follow-up, mo . |
|---|---|---|---|---|---|---|---|---|
| Alemtuzumab 24 mg/d | ||||||||
| 1 | 39 (M) | 2 (192) | 19 (7) | 4 | Fatal ICH | None | NA* | NA* |
| 2 | 37 (F) | 3 (264) | 36 (12) | 4 | Petechiae | PT, M | 1 | 34 |
| 3 | 30 (M) | 2 (192) | 24 (12) | 2 | Ecchymoses | M, PT, IG, P, Da, De, Ri | 4 | 46 |
| 4 | 34 (F) | 2 (192) | 21 (9) | 3 | None | P | 6 | 33 |
| Alemtuzumab 12 mg/d | ||||||||
| 5 | 34 (F) | 3 (132) | 39 (15) | 41 | None | None | 3 | 36 |
| 6 | 49 (F) | 3 (132) | 25 (1) | 1 | Petechiae | De, PT, P, Rh, H, Ri | 8 | 34 |
| SC IFNB-1a | ||||||||
| 7 | 42 (F) | NA | 3 (NA) | 62 | None | None | 21 | 11 |
| Subject ID . | Age at ITP onset, y (sex) . | No. of alemtuzumab cycles (cumulative dose, mg) . | Months from first dose (last dose) to ITP onset . | Platelet count nadir, 109/L . | Presenting signs or symptoms . | ITP therapy . | Months from ITP onset to CR . | Duration of CR at last follow-up, mo . |
|---|---|---|---|---|---|---|---|---|
| Alemtuzumab 24 mg/d | ||||||||
| 1 | 39 (M) | 2 (192) | 19 (7) | 4 | Fatal ICH | None | NA* | NA* |
| 2 | 37 (F) | 3 (264) | 36 (12) | 4 | Petechiae | PT, M | 1 | 34 |
| 3 | 30 (M) | 2 (192) | 24 (12) | 2 | Ecchymoses | M, PT, IG, P, Da, De, Ri | 4 | 46 |
| 4 | 34 (F) | 2 (192) | 21 (9) | 3 | None | P | 6 | 33 |
| Alemtuzumab 12 mg/d | ||||||||
| 5 | 34 (F) | 3 (132) | 39 (15) | 41 | None | None | 3 | 36 |
| 6 | 49 (F) | 3 (132) | 25 (1) | 1 | Petechiae | De, PT, P, Rh, H, Ri | 8 | 34 |
| SC IFNB-1a | ||||||||
| 7 | 42 (F) | NA | 3 (NA) | 62 | None | None | 21 | 11 |
De indicates dexamethasone; PT, platelet transfusion; P, prednisone; Rh, anti-Rh(D) immune globulin; H, hydrocortisone; Ri, rituximab; ICH, intracranial hemorrhage; NA, not applicable; M, methylprednisolone; IG, intravenous IgG; and Da, danazol.
Patient died of ICH at presentation of ITP.